N-Acetyl-Ser-Asp-Lys-Pro NEW
| Price | $30 | $61 | $103 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: N-Acetyl-Ser-Asp-Lys-Pro | CAS No.: 127103-11-1 |
| Purity: 99.85% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | N-Acetyl-Ser-Asp-Lys-Pro |
| Description | Acetyl Ser-Asp-Lys-Pro is formed in bone marrow cells by enzymatic processing of thymosin β4. It inhibits the entry of pluripotent hemopoietic stem cells into S-phase of the cell cycle and protects against Ara-C lethality in mice. |
| In vitro | N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP) is a specific substrate for the N-terminal site of ACE and increases five-fold during ACE inhibitor therapy. AcSDKP inhibited the proliferation of isolated cardiac fibroblasts (P<0.05) but significantly stimulated the proliferation of vascular smooth muscle cells. Flow cytometry of rat cardiac fibroblasts treated with AcSDKP showed significant inhibition of cell progression from G0/G1 phase to S phase. In cardiac fibroblasts transfected with a Smad-sensitive luciferase reporter construct, AcSDKP decreased luciferase activity by 55±9.7% (P=0.01). Additionally, AcSDKP decreased phosphorylation and nuclear translocation of Smad2 in cardiac fibroblasts. In conclusion, AcSDKP inhibits the growth of cardiac fibroblasts and TGFbeta1-stimulated phosphorylation of Smad2. Because AcSDKP increases substantially during ACE inhibitor therapy, this suggests a novel pathway independent of angiotensin II by which ACE inhibitors can inhibit cardiac fibrosis. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 10 mM |
| Keywords | Ac-SDKP | NAcetylSerAspLysPro | Inhibitor | N-Acetyl-Ser-Asp-Lys-Pro | inhibit | N Acetyl Ser Asp Lys Pro | Angiotensin-converting Enzyme (ACE) |
| Inhibitors Related | Tranilast | Enalapril Maleate | Sacubitril/Valsartan | Irbesartan | Losartan | Captopril |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Peptide Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1Gram |
VIP1Y
|
Hangzhou Hyper Chemicals Limited
|
2024-06-17 | |
| $25.00/1box |
VIP1Y
|
Shanghai Getian Industrial Co., LTD
|
2024-05-17 | |
| $0.00/1g |
VIP1Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-04-17 | |
| $30.00/1box |
VIP1Y
|
hebei hongtan Biotechnology Co., Ltd
|
2024-03-21 | |
| $30.00/1Box |
zhuzhou dingcheng meihei comestic co.,ltd
|
2023-12-20 | ||
| $10.00/1kg |
Nantong Guangyuan Chemicl Co,Ltd
|
2023-11-15 | ||
| $50.00/1g |
Shanghai Yunao International Trade Co., Ltd
|
2023-10-12 | ||
| $45.00/1kg |
Henan Bao Enluo International TradeCo.，LTD
|
2023-05-18 | ||
| $0.00/10g |
Shanghai Yunao International Trade Co., Ltd
|
2023-10-11 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY